Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Breast Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 59 (final count)
- Started
- Aug 9, 2023
- Main results expected
- Dec 30, 2026
- Fully finished
- Dec 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Study Lead-in (SLI): Incidence of Grade 4 neutropenia
Measured over: From randomization date up to Cycle 4 (each cycle is 28 days).
SLI: Incidence of dose reduction
Measured over: From randomization date up to Cycle 4 (each cycle is 28 days).
SLI: Incidence of drug discontinuation.
Measured over: From randomization date up to Cycle 4 (each cycle is 28 days).
Phase 3: Progression-Free Survival
Measured over: From randomization date, every 12 weeks, to date of first documentation of progression or death, up to approximately 4 years.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05909397 · record last updated 2026-02-10 · checked 2026-11-09 15:42 UTC